Radiopharm Theranostics (RADX) Short term Debt (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Radiopharm Theranostics (RADX) has disclosed Short term Debt for 2 consecutive years, with $3.4 million as the latest value for Q2 2025.

• Quarterly Short term Debt fell 45.86% to $3.4 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Jun 2025, down 45.86% year-over-year, with the annual reading at $3.4 million for FY2025, 45.86% down from the prior year.
• Short term Debt for Q2 2025 was $3.4 million at Radiopharm Theranostics, down from $6.3 million in the prior quarter.
• The five-year high for Short term Debt was $6.3 million in Q2 2024, with the low at $3.4 million in Q2 2025.

Peer Comparison